DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
DBV Technologies (DBVT) has announced that its Chief Executive Officer, Daniel Tassé, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. The event is scheduled for Wednesday, May 7, 2025, at 11:00am ET in New York, NY. Investors and interested parties can access a live webcast of the presentation through the company's website, and a replay will be available for 90 days following the event.
DBV Technologies (DBVT) ha annunciato che il suo Amministratore Delegato, Daniel Tassé, parteciperà a una conversazione informale durante la Citizens JMP Life Sciences Conference. L'evento è previsto per mercoledì 7 maggio 2025 alle 11:00 ET a New York, NY. Investitori e interessati potranno seguire una diretta streaming della presentazione tramite il sito web dell'azienda, e sarà disponibile una replica per 90 giorni dopo l'evento.
DBV Technologies (DBVT) ha anunciado que su Director Ejecutivo, Daniel Tassé, participará en una charla informal en la Citizens JMP Life Sciences Conference. El evento está programado para el miércoles 7 de mayo de 2025 a las 11:00 am ET en Nueva York, NY. Los inversores y partes interesadas podrán acceder a una transmisión en vivo de la presentación a través del sitio web de la compañía, y una repetición estará disponible durante 90 días después del evento.
DBV Technologies (DBVT)는 최고경영자(CEO) 다니엘 타세가 Citizens JMP 생명과학 컨퍼런스에서 대담에 참여할 예정이라고 발표했습니다. 행사는 2025년 5월 7일 수요일 오전 11시(동부시간) 뉴욕에서 개최됩니다. 투자자 및 관심 있는 분들은 회사 웹사이트를 통해 생중계로 발표를 시청할 수 있으며, 행사가 끝난 후 90일 동안 다시보기 서비스도 제공됩니다.
DBV Technologies (DBVT) a annoncé que son directeur général, Daniel Tassé, participera à une discussion informelle lors de la Citizens JMP Life Sciences Conference. L'événement est prévu pour le mercredi 7 mai 2025 à 11h00 ET à New York, NY. Les investisseurs et parties intéressées pourront accéder à une diffusion en direct de la présentation via le site web de la société, et un replay sera disponible pendant 90 jours après l'événement.
DBV Technologies (DBVT) hat bekannt gegeben, dass sein Geschäftsführer Daniel Tassé an einem Gespräch im Rahmen der Citizens JMP Life Sciences Conference teilnehmen wird. Die Veranstaltung findet am Mittwoch, den 7. Mai 2025, um 11:00 Uhr ET in New York, NY, statt. Investoren und Interessierte können die Präsentation live über die Website des Unternehmens verfolgen, und eine Aufzeichnung wird für 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Châtillon, France, May 5, 2025
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY.
A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/
A replay will also be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
When is DBV Technologies (DBVT) presenting at the Citizens JMP Life Sciences Conference 2025?
How can I watch DBV Technologies' (DBVT) presentation at the Citizens JMP Life Sciences Conference?
How long will the replay of DBVT's Citizens JMP Conference presentation be available?
Who will represent DBV Technologies (DBVT) at the Citizens JMP Life Sciences Conference 2025?
